Multimeric Immunotoxins for Cancer Treatment and Graft vs Host Disease

Technology No. z00021
IP Status: Issued US Patent; Application #: 09/440,344

Multimeric Immunotoxins with Cytocines Localize in Cancer Target Tissue

A technique has been created to produce multimeric immunotoxins. These immunotoxins are recombinant proteins form using c-terminal bridging techniques. By adding a second antibody for antigens expressed on cancer target cells, the researchers can narrow the spectrum of cells that the toxin can enter, thus improving the efficacy of treatment and reducing nontarget treatment.
Immunotoxins have a major advantage of killing both dividing and non-dividing target cells and are directed against the protein synthesis machinery of the cell. Potent anti-cancer cytokine immunotoxins can be expressed as single chain recombinant proteins by splicing genes of potent catalytic toxins to cytokine genes that selectively bind target cells and kill them. These multimeric immunotoxins also show potential for overcoming rejection in graft versus host disease (GVHD).

MN-IP Try and Buy
  • Trial period of 12 to 18 months. $5,000/6 months.
  • Fee waived if MN-based company or if sponsoring $50.000+ in research.
  • Exclusive license for a $20,000 conversion payment.
  • No patent costs due.
  • 3% royalty after $1 million of product sales.
  • Discount for MN companies.

Immunotoxins for Cancer Treatment

Immunotoxins are one approach to improving the delivery of cancer drugs, reducing non target treatment and side effects. Immunotoxins are synthesized proteins that provide targeted delivery of toxins by pairing them with an antibody. The antibody binds to an antigen on the surface of the cancer target cell and the toxin is taken into the cell by endocytosis. Such agents have shown promise in previous clinical studies, but they have been limited by two major problems: 1) failure to localize in adequate concentrations in cancer target tissue 2) localization in nontarget organs such as the kidneys limiting the tolerated dose and collapsing the therapeutic window.


  • Immunotoxins localize to the cancer target, increasing effectiveness and lowering the toxic side effects of treatment
  • Therapeutic dose has decreased renal toxicity
  • Creates therapeutic window where none existed before by increasing the tolerable dosage
  • Bridging technique can be applied to other immunotoxins
  • Multimeric immunotoxins help overcome GVHD and could become a more effective anti-rejection medication allowing transplanted cells to survive long after implantation

Researchers: Daniel Vallera, PhD Professor, Department of Therapeutic Radiology
Bruce Blazer,MD Regents Professor, Department of Pediatrics, Division of Blood and Marrow Transplantation
  • swap_vertical_circlecloud_downloadSupporting documents (0)
Questions about this technology?